MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer

Genes and Development

Volumn 23, Issue 18, 2009, Pages 2152-2165

  Olson, Peter ^a,b   Lu, Jun ^c,d   Zhang, Hao ^c   Shai, Anny ^a,b   Chun, Matthew G ^a,b   Wang, Yucheng ^b   Libutti, Steven K ^e   Nakakura, Eric K ^b   Golub, Todd R ^c,f   Hanahan, Douglas ^a,b,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g EPFL   (Switzerland)

Author keywords

Cancer; MicroRNA; miR 200; Mouse model of human cancer; Pancreatic neuroendocrine tumor (PNET); Transgenic mouse

Indexed keywords

ANGIOGENESIS INHIBITOR; MICRORNA; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTOME; UNCLASSIFIED DRUG; UVOMORULIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; LIVER METASTASIS; METASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; RNA FINGERPRINTING;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MICE; MICE, INBRED C57BL; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 70349145414     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1820109     Document Type: Article

References (79)

1. Ambros V. 2004. The functions of animal microRNAs. Nature 431: 350-355.
2. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
3. Bergers G, Hanahan D. 2008. Modes of resistance to antiangiogenic therapy. Natl Rev 8: 592-603.
4. Bernards R, Weinberg RA. 2002. A progression puzzle. Nature 418: 823.
5. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. 2007. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908. (Pubitemid 46707844)
6. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. 2003. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4: 133-146. (Pubitemid 37040829)
7. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. 2008. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9: 582-589. (Pubitemid 351772923)
8. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Natl Rev 6: 857-866.
9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci 99: 15524-15529. (Pubitemid 35403967)
10. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al. 2004. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci 101: 11755-11760. (Pubitemid 39095368)
11. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al. 2005. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801. (Pubitemid 41549891)
12. Casanovas O, Hager JH, Chun MG, Hanahan D. 2005a. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene 24: 6597-6604. (Pubitemid 41486790)
13. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. 2005b. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309. (Pubitemid 41443415)
14. Chan JA, Krichevsky AM, Kosik KS. 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033. (Pubitemid 40994386)
15. Choi PS, Zakhary L, Choi WY, Caron S, Alvarez-Saavedra E, Miska EA, McManus M, Harfe B, Giraldez AJ, Horvitz HR, et al. 2008. Members of the miRNA-200 family regulate olfactory neurogenesis. Neuron 57: 41-55.
16. Christofori G, Naik P, Hanahan D. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-418. (Pubitemid 24184057)
17. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. 2005. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358. (Pubitemid 41074723)
18. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. 2006. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci 103: 7024-7029.
19. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C,Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, et al. 2006. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065. (Pubitemid 44325933)
20. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. 2009. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
21. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. 2005. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci 102: 3627-3632. (Pubitemid 40354662)
22. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764.
23. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. 2008. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15: 272-284.
24. Folkman J, Watson K, Ingber D, Hanahan D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61. (Pubitemid 19115892)
25. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, et al. 2009. Contextual cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes & Dev (this issue). doi: 10.1101/gad.1820209.
26. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. 2008. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-oncol 10: 940-945.
27. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601. (Pubitemid 351627379)
28. Hanahan D. 1985. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122. (Pubitemid 15064530)
29. Hanahan D. 1988. Dissecting multistep tumorigenesis in transgenic mice. Annu Rev Genet 22: 479-519. (Pubitemid 19156672)
30. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
31. Hanahan D, Christofori G, Naik P, Arbeit J. 1996. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 32A: 2386-2393. (Pubitemid 27080776)
32. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al. 2005. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci 102: 19075-19080. (Pubitemid 43049568)
33. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al. 2005. A microRNA polycistron as a potential human oncogene. Nature 435: 828-833. (Pubitemid 40839734)
34. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. 1992. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes & Dev 6: 177-185.
35. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, et al. 2001. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 29: 459-464. (Pubitemid 34326698)
36. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070. (Pubitemid 41161233)
37. Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. 2007. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell 131: 136-145. (Pubitemid 47498538)
38. Kennell JA, Gerin I, MacDougald OA, Cadigan KM. 2008. The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad Sci 105: 15417-15422.
39. Kloosterman WP, Plasterk RH. 2006. The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450. (Pubitemid 44430905)
40. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al. 2007. A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
41. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci 105: 3903-3908. (Pubitemid 351723497)
42. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. 2007. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054. (Pubitemid 46214304)
43. Lin SP, Youngson N, Takada S, Seitz H, Reik W, Paulsen M, Cavaille J, Ferguson-Smith AC. 2003. Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet 35: 97-102. (Pubitemid 37048602)
44. Lopez T, Hanahan D. 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1: 339-353. (Pubitemid 41039136)
45. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. 2005. MicroRNA expression profiles classify human cancers. Nature 435: 834-838. (Pubitemid 40839735)
46. Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, Pretz J, Schlanger R, Wang JY, Mak RH, et al. 2008. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 14: 843-853. (Pubitemid 351757199)
47. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, et al. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971. (Pubitemid 46975753)
48. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891.
49. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. 2006. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545.
50. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al. 2008. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787.
51. Nozawa H, Chiu C, Hanahan D. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci 103: 12493-12498. (Pubitemid 44267286)
52. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci 104: 1604-1609. (Pubitemid 46214637)
53. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. 2005. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
54. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
55. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, et al. 2006. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13: 497-508. (Pubitemid 43886672)
56. Parangi S, Dietrich W, Christofori G, Lander ES, Hanahan D. 1995. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res 55: 6071-6076.
57. Park SM, Gaur AB, Lengyel E, Peter ME. 2008. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & Dev 22: 894-907.
58. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193. (Pubitemid 28162793)
59. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, et al. 2008. E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272-286. (Pubitemid 351318375)
60. Pietras K, Hanahan D. 2005. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952.
61. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, et al. 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316: 608-611. (Pubitemid 46683148)
62. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, et al. 2006. Micro-RNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677-4684. (Pubitemid 46630931)
63. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA. 2000. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2: 306-314. (Pubitemid 30703463)
64. Shingara J, Keiger K, Shelton J, Laosinchai-Wolf W, Powers P, Conrad R, Brown D, Labourier E. 2005. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 11: 1461-1470. (Pubitemid 41215448)
65. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. 2007. miR-21-mediated tumor growth. Oncogene 26: 2799-2803.
66. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. 2005. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48-55. (Pubitemid 40070939)
67. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA. 2007. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452. (Pubitemid 47014466)
68. Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci 103: 12481-12486. (Pubitemid 44267285)
69. Tavazoie SF, Alarcon C, Oskarsson T, Padua D,Wang Q, Bos PD, Gerald WL, Massague J. 2008. Endogenous human micro-RNAs that suppress breast cancer metastasis. Nature 451: 147-152.
70. Teitelman G, Alpert S, Hanahan D. 1988. Proliferation, senescence, and neoplastic progression of β cells in hyperplasic pancreatic islets. Cell 52: 97-105. (Pubitemid 18054593)
71. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et al. 2007. Regulation of the germinal center response by micro-RNA-155. Science 316: 604-608. (Pubitemid 46683147)
72. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, et al. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886. (Pubitemid 351312807)
73. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 103: 2257-2261. (Pubitemid 43271657)
74. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. 2008. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271.
75. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen S, Plasterk RH. 2005. MicroRNA expression in zebrafish embryonic development. Science 309: 310-311. (Pubitemid 40967869)
76. Woods K, Thomson JM, Hammond SM. 2007. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 282: 2130-2134. (Pubitemid 47076737)
77. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al. 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198. (Pubitemid 43357945)
78. Zender L, Lowe SW. 2008. Integrative oncogenomic approaches for accelerated cancer-gene discovery. Curr Opin Oncol 20: 72-76. (Pubitemid 350190984)
79. Zhu S, Si ML, Wu H, Mo YY. 2007. MicroRNA-21 Targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336. (Pubitemid 47100416)